HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bestrophin-1 influences transepithelial electrical properties and Ca2+ signaling in human retinal pigment epithelium.

AbstractPURPOSE:
Mutations in BEST1, encoding Bestrophin-1 (Best1), cause Best vitelliform macular dystrophy (BVMD) and other inherited retinal degenerative diseases. Best1 is an integral membrane protein localized to the basolateral plasma membrane of the retinal pigment epithelium (RPE). Data from numerous in vitro and in vivo models have demonstrated that Best1 regulates intracellular Ca2+ levels. Although it is known from in vitro and crystal structure data that Best1 is also a calcium-activated anion channel, evidence for Best1 functioning as a channel in human RPE is lacking. To assess Best1-associated channel activity in the RPE, we examined the transepithelial electrical properties of fetal human RPE (fhRPE) cells, which express endogenous Best1.
METHODS:
Using adenovirus-mediated gene transfer, we overexpressed Best1 and the BVMD mutant Best1W93C in fhRPE cells and assessed resting transepithelial potential (TEP), transepithelial resistance, short circuit current (Isc), and intracellular Ca2+ levels. Cl- currents were directly measured in transfected HEK293 cells using whole-cell patch clamp.
RESULTS:
Best1W93C showed ablated Cl- currents and, when co-expressed, suppressed the channel activity of Best1 in HEK293 cells. In fhRPE, overexpression of Best1 increased TEP and Isc, while Best1W93C diminished TEP and Isc. Substitution of Cl- in the bath media resulted in a significant reduction of Isc in monolayers overexpressing Best1, but no significant Isc change in monolayers expressing Best1W93C. We removed Ca2+ as a limit on transepithelial electrical properties by treating cells with ionomycin, and found that changes in Isc and TEP for monolayers expressing Best1 were absent in monolayers expressing Best1W93C. Similarly, inhibition of calcium-activated anion channels with niflumic acid reduced both Isc and TEP of control and Best1 monolayers, but did not notably affect Best1W93C monolayers. Stimulation with extracellular ATP induced an increase in TEP in control monolayers that was greater than that observed in those expressing Best1(W93C). Examination of [Ca2+]i following ATP stimulation demonstrated that the expression of Best1W93C impaired intracellular Ca2+ signaling.
CONCLUSIONS:
These data indicate that Best1 activity strongly influences electrophysiology and Ca2+ signaling in RPE cells, and that a common BVMD mutation disrupts both of these parameters. Our findings support the hypothesis that Best1 functions as an anion channel in human RPE.
AuthorsAlan D Marmorstein, Tyson R Kinnick, J Brett Stanton, Adiv A Johnson, Ronald M Lynch, Lihua Y Marmorstein
JournalMolecular vision (Mol Vis) Vol. 21 Pg. 347-59 ( 2015) ISSN: 1090-0535 [Electronic] United States
PMID25878489 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • BEST1 protein, human
  • Bestrophins
  • Chloride Channels
  • Eye Proteins
  • Niflumic Acid
  • Ionomycin
  • Adenosine Triphosphate
  • Calcium
Topics
  • Adenosine Triphosphate (pharmacology)
  • Adenoviruses, Human (genetics)
  • Bestrophins
  • Calcium (metabolism)
  • Calcium Signaling
  • Cell Membrane (drug effects, metabolism)
  • Chloride Channels (genetics, metabolism)
  • Epithelial Cells (cytology, drug effects, metabolism)
  • Eye Proteins (genetics, metabolism)
  • Fetus
  • Gene Expression
  • Genetic Vectors
  • HEK293 Cells
  • Humans
  • Ion Transport (drug effects)
  • Ionomycin (pharmacology)
  • Membrane Potentials (drug effects)
  • Mutation
  • Niflumic Acid (pharmacology)
  • Patch-Clamp Techniques
  • Primary Cell Culture
  • Retinal Pigment Epithelium (cytology, drug effects, metabolism)
  • Transfection
  • Vitelliform Macular Dystrophy (genetics, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: